Previous 10 | Next 10 |
home / stock / soltf / soltf news
Sosei Heptares to Regain Worldwide Rights to Muscarinic Agonist Programs PR Newswire TOKYO and CAMBRIDGE, England , Jan. 5, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) announces it is to regain the worldwide rights to i...
Sosei Heptares and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design - Program focused on identifying small molecules that target a GPCR for degradation as potential therapeutic agents for gastroin...
Sosei Heptares and GSK Enter Global Collaboration and License Agreement Targeting Immune Disorders of the Digestive System - Single-target agreement focused on small molecule agonists of GPR35, a genetically validated target for inflammatory bowel disease and other gastrointesti...
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) inks a global collaboration and license agreement with Tokyo's Sosei Group (SOLTF) aimed at developing a portfolio of the latter's small molecule calcitonin gene-related peptide ((CGRP)) receptor antagonists for CGRP-mediated disorders. ...
Sosei Heptares and Biohaven Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio - Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists - The lead candidate, HTL0022562, has a...
Sosei Heptares' COVID-19 Program Identifies Potent Broad Spectrum Anti-Viral Small Molecules for Further Development - Program focused on inhibitors of SARS-CoV-2 main protease, a highly conserved protein essential for viral replication - Structure-based design approach has ...
Sosei Group (SOLTF): 9M net loss of $15.0M.Revenue of $41M (-42.3% Y/Y)Press Release For further details see: Sosei Group reports 9M results
Sosei Group (SOLTF) announced that Sosei Heptares has earned a $5M milestone payment from collaboration partner Pfizer (PFE) triggered by the dosing of the first subject in a clinical trial.Last year, Pfizer nominated three candidates under the partnership, two of which have en...
TOKYO and CAMBRIDGE, England , Sept. 3, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) today announces the appointment of Hironoshin Nomura, as Senior Vice President Investor Relations and Corporate Strategy. Mr. Nomura, who will lead the Sosei Heptares IR...
Sosei Group ( OTCPK:SOLTF ) : 1H net loss of $19.6M More news on: Sosei Group Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Sosei Co Ltd Ord Company Name:
SOLTF Stock Symbol:
OTCMKTS Market:
Tokyo, Japan and Cambridge, UK, 9 July 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for the 6 months ended 30 June 2024 on Friday, 9 August 2024. The Company will host a live webinar presentation with C...
Tokyo, Japan and Cambridge, UK, 27 June 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration with AbbVie targeting neurological diseases, resulting in a payment of US$10 million...
Tokyo, Japan and Cambridge, UK, 18 June 2024 – Nxera Pharma (“Nxera” or “the Company”; TSE 4565), today announces the publication of its Annual Report and its Environment, Social & Governance (ESG) Report for the year ended 31 December 2023. The Annu...